비교리스트

 카트 문의
시장보고서
상품코드
1514052

세계의 HTS(High Throughput Screening) 시장

High Throughput Screening (HTS)
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 273 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 HTS(High Throughput Screening) 시장은 2030년까지 453억 달러에 이를 것으로 예상

2023년에 404억 달러로 평가된 세계의 HTS(High Throughput Screening) 시장은 분석기간 2023년부터 2030년까지 CAGR 1.6%로 성장할 전망이며, 2030년에는 453억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 HTS 소모품 및 시약은 CAGR 3.7%로 성장을 지속하고, 분석 기간 종료 시 169억 달러에 도달할 것으로 예측됩니다. HTS 소모품 및 시약 부문 분석 기간 중 CAGR 성장률은 6.9%로 추정됩니다.

미국 시장은 106억 달러, 중국은 CAGR 5.9%로 성장 예측

미국의 HTS(High Throughput Screening) 시장은 2023년 106억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 113억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023년부터 2030년까지 CAGR은 5.9%로 전망됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 CAGR은 각각 -2.4%와 1.0%로 예측됩니다. 유럽에서는 독일이 CAGR-1.1% 정도로 성장할 것으로 예측되고 있습니다.

세계의 HTS(High Throughput Screening) 시장-주요 동향 및 촉진요인 요약

HTS(High Throughput Screening)은 신약으로 발전할 수 있는 리드 화합물을 확인하기 위한 효율적인 접근법을 제공하며, 의약품 개발 및 학술 연구의 기초가 되는 방법이 되었습니다. 자동화, 고급 소프트웨어 및 풍부한 화합물 라이브러리를 활용함으로써 HTS는 주로 세포 내 과정에서 중요한 역할을하는 단백질과 같은 생물학적 표적에 대한 많은 화합물을 신속하게 평가할 수 있습니다. 1980년대 후반에 도입된 HTS는 주요 제약사의 천연물 스크리닝을 신속하게 함으로써 각광을 받고, 임상 진단이나 산업 생명공학 등 다양한 분야에서 응용이 확산되고 있습니다. 수백만의 화합물을 신속하게 체질하고 잠재적인 치료 효과를 가진 화합물을 확인하는 능력은 약물의 속도를 가속화하는 데 매우 중요합니다. 이 스크리닝 방법은 다재다능하고 in vitro와 in vivo 모두에서 화합물을 평가할 수 있으므로 표적에 대한 자세한 지식 없이도 세포 및 생리적 종점의 조절자를 발견할 수 있습니다.

HTS는 질병 경로 및 창약 표적으로서의 중요성으로부터 효소를 표적으로 할 때 특히 효과적입니다. 키나아제와 같은 효소는 암과 염증성 질환을 포함한 많은 세포내 과정과 질병에 관여하며, HTS 캠페인에서 자주 표적이 됩니다. 이러한 스크리닝에서 주된 검출 방법은 종종 형광 기반 분석법을 사용하지만, 이는 고감도임에도 불구하고 간섭이나 위양성을 일으키기 쉽습니다. 이러한 문제를 완화하기 위해 HTS 분석은 결과를 잘못 만드는 응집물을 피하기 위해 세제를 첨가하는 등 특별한 고려 사항으로 설계되었습니다. 일단 분석이 개발되고 유효성이 확인되면, HTS는 최신 자동화 플랫폼을 사용하여 1차 스크리닝 형식으로 확장할 수 있습니다. 이 단계에서는 로봇 공학, 첨단 액체 처리 장치, 고감도 검출기가 통합되어 스크리닝이 효율적이고 효과적으로 수행됩니다. 히트 화합물의 식별부터 리드 화합물의 최적화까지의 과정에서는 화합물의 흡수, 분포, 대사, 배설(ADME), 독성 등의 주요 약물 특성을 조사할 필요가 있으며, 창약의 초기 단계에서 HTS의 중요한 역할이 강조됩니다.

HTS의 진화는 기술적, 과학적 진보에 의해 그 수법이 형성되어 그 영향력과 효율이 높아지는 가운데 계속되고 있습니다. 인공지능과 머신러닝의 통합으로 데이터 분석 능력이 강화되어 복잡한 데이터 세트를 보다 깊게 해석할 수 있게 되었습니다. 마이크로칩 기반의 시스템과 나노리터 분주 기술의 채용과 같은 분석 기술의 혁신은 스크리닝의 정확성을 높이고 필요한 리소스를 줄입니다. HTS의 주요 성장 촉진요인으로는 자동화와 로봇 공학의 진보, 마이크로플루이딕스공학과 나노기술의 이용, 맞춤형 의료 수요 증가 등을 들 수 있으며, HTS는 독자적인 바이오마커를 동정하여 맞춤형 치료법을 개발하는 데 사용됩니다. 게다가 생물제제와 특수의약품의 확대, 지지적인 규제환경, 창약자금 증가 등이 HTS의 채용을 뒷받침하고 있습니다. 학술계와 제약업계와의 협력관계도 불가결하며 지식교환을 촉진하고 HTS 기술의 구현을 강화함으로써 세계의 건강위기와 효과적인 의약품의 신속한 개발이라는 사회적 요구에 부응 위에서 특히 중요한 역할을 합니다.

조사 대상 기업 예(총 41건)

  • Agilent Technologies, Inc.
  • Aurora Biomed Inc.
  • Axxam SpA
  • BD Biosciences
  • Beckman Coulter Inc.
  • Bio-Rad Laboratories Inc.
  • BioTek Instruments Inc.
  • BMG LABTECH GmbH
  • Charles River Laboratories International Inc.
  • Corning Inc.
  • Danaher Corporation
  • Evotec AG
  • F. Hoffmann-La Roche Ltd.
  • Genedata AG
  • IntelliCyt(R)Corporation
  • Luminex Corporation
  • Molecular Devices Inc.
  • Pall ForteBio LLC
  • PerkinElmer Inc.
  • Sigma-Aldrich Corp.
  • Tecan Group Ltd.
  • Thermo Fischer Scientific Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

AJY 24.07.24

Global High Throughput Screening (HTS) Market to Reach US$45.3 Billion by 2030

The global market for High Throughput Screening (HTS) estimated at US$40.4 Billion in the year 2023, is expected to reach US$45.3 Billion by 2030, growing at a CAGR of 1.6% over the analysis period 2023-2030. HTS Consumables / Reagents, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$16.9 Billion by the end of the analysis period. Growth in the HTS Consumables/Reagents segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.6 Billion While China is Forecast to Grow at 5.9% CAGR

The High Throughput Screening (HTS) market in the U.S. is estimated at US$10.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$11.3 Billion by the year 2030 trailing a CAGR of 5.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of -2.4% and 1.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately -1.1% CAGR.

Global High Throughput Screening (HTS) Market - Key Trends and Drivers Summarized

High Throughput Screening (HTS) has become a cornerstone methodology in pharmaceutical development and academic research, providing an efficient approach to identifying lead compounds that might evolve into new drugs. Utilizing automation, sophisticated software, and extensive chemical libraries, HTS facilitates the rapid evaluation of numerous compounds against biological targets, mainly proteins, which play critical roles in cellular processes. Introduced in the late 1980s, HTS gained prominence by expediting natural product screenings at major pharmaceutical companies and has expanded its application across various sectors including clinical diagnostics and industrial biotechnology. The ability to quickly sift through millions of compounds and identify those with potential therapeutic effects is invaluable in accelerating the pace of drug discovery. This screening method is versatile, allowing both in vitro and in vivo settings to assess compounds, thereby enabling the discovery of modulators of cellular or physiological endpoints without prior detailed knowledge of the target.

HTS is particularly effective in targeting enzymes due to their significance in disease pathways and as drug targets. Enzymes like kinases, which are involved in many cellular processes and diseases, including cancer and inflammatory disorders, are frequent targets in HTS campaigns. The primary detection methods in these screenings often use fluorescence-based assays, which, despite their high sensitivity, are prone to interference and false positives. To mitigate these issues, HTS assays are designed with specific considerations, such as the inclusion of detergents to avoid aggregates that cause misleading results. Once an assay is developed and validated, HTS can be scaled to a primary screening format using modern automation platforms. This phase integrates robotics, sophisticated liquid handling devices, and sensitive detectors, ensuring that the screenings are conducted efficiently and effectively. The process from hit identification to lead optimization involves scrutinizing compounds for key drug properties such as absorption, distribution, metabolism, excretion (ADME), and toxicity, underscoring HTS's critical role in the early stages of drug discovery.

The evolution of HTS continues with technological and scientific advancements shaping its methodologies and increasing its impact and efficiency. The integration of artificial intelligence and machine learning enhances data analysis capabilities, allowing for a deeper interpretation of complex datasets. Innovations in assay technology, such as the adoption of microchip-based systems and nanoliter dispensing technologies, are refining the precision and reducing the resource requirements of screenings. The major drivers of growth in HTS include advancements in automation and robotics, the use of microfluidics and nanotechnology, and the increasing demand for personalized medicine, which relies on HTS for identifying unique biomarkers and developing tailored therapies. Moreover, the expansion of biologics and specialty pharmaceuticals, along with supportive regulatory environments and increased funding for drug discovery, are bolstering the adoption of HTS. Collaborations between academia and the pharmaceutical industry are also vital, facilitating knowledge exchange and enhancing the implementation of HTS technologies, particularly critical in responding to global health crises and the public demand for rapid development of effective medications.

Select Competitors (Total 41 Featured) -

  • Agilent Technologies, Inc.
  • Aurora Biomed Inc.
  • Axxam SpA
  • BD Biosciences
  • Beckman Coulter Inc.
  • Bio-Rad Laboratories Inc.
  • BioTek Instruments Inc.
  • BMG LABTECH GmbH
  • Charles River Laboratories International Inc.
  • Corning Inc.
  • Danaher Corporation
  • Evotec AG
  • F. Hoffmann-La Roche Ltd.
  • Genedata AG
  • IntelliCyt(R) Corporation
  • Luminex Corporation
  • Molecular Devices Inc.
  • Pall ForteBio LLC
  • PerkinElmer Inc.
  • Sigma-Aldrich Corp.
  • Tecan Group Ltd.
  • Thermo Fischer Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • High Throughput Screening (HTS) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Drug Discovery and Development Propels Growth in HTS Market
    • Advances in Automation and Robotics Strengthen Business Case for High Throughput Screening Adoption
    • Increasing Focus on Personalized Medicine Expands Addressable Market Opportunity
    • Technological Innovations in Assay Development Drive Market Growth
    • Growing Use of HTS in Genomics and Proteomics Accelerates Market Penetration
    • Integration of AI and Machine Learning in HTS Throws the Spotlight on Enhanced Data Analysis and Prediction
    • Rising Investment in Biotechnology and Life Sciences Expands Market Scope for HTS Solutions
    • Advances in Miniaturization and Microfluidics Propel Development of High-Performance HTS Systems
    • Focus on Reducing Drug Development Costs and Time-to-Market Spurt Demand for HTS Technologies
    • Increasing Adoption of HTS in Academic and Research Institutions Boost Market Penetration
    • Development of Novel High Content Screening (HCS) Technologies Expands Addressable Market Opportunity
    • Rising Demand for Toxicology Testing and Safety Assessment Drives Adoption of HTS
    • Expansion of Drug Repurposing and Combination Screening Initiatives Spurs Market Growth
    • Increasing Use of HTS in Agricultural and Environmental Sciences Expands Market Reach
    • Development of User-Friendly and Scalable HTS Platforms Enhances Market Adoption
    • Rising Importance of Target-Based and Phenotypic Screening Strengthens Business Case for HTS
    • Growing Adoption of HTS in Stem Cell Research and Regenerative Medicine Expands Market Scope
    • Focus on Enhancing Screening Efficiency and Throughput Drives Market Innovation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for High Throughput Screening (HTS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for High Throughput Screening (HTS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Consumables/Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Consumables/Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Consumables/Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Cell-based Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Cell-based Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Cell-based Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Label-Free Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Label-Free Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Label-Free Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Target Identification & Validation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Target Identification & Validation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Target Identification & Validation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Primary & Secondary Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Primary & Secondary Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Primary & Secondary Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Toxicology Assessment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Toxicology Assessment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Toxicology Assessment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 33: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 36: World 16-Year Perspective for Pharmaceutical & Biotechnology Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Academic & Government Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Academic & Government Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 39: World 16-Year Perspective for Academic & Government Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Contract Research Organizations (CRO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 41: World Historic Review for Contract Research Organizations (CRO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 42: World 16-Year Perspective for Contract Research Organizations (CRO) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 43: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 44: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 45: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 46: World Recent Past, Current & Future Analysis for Consumables / Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 47: World Historic Review for Consumables / Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 48: World 16-Year Perspective for Consumables / Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 49: World High Throughput Screening (HTS) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 50: USA Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: USA 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: USA 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: USA 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: USA 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 62: Canada Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Canada 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 74: Japan Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Japan 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Japan 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 86: China Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: China Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: China 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: China Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: China 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: China Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: China 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 95: China Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: China Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: China 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 98: Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for High Throughput Screening (HTS) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for High Throughput Screening (HTS) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Europe 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Europe 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Europe 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 113: France Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: France Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: France 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: France Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: France 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: France Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: France 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 122: France Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: France Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: France 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 125: Germany Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Germany 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Germany 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Germany 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 134: Germany Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Germany 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 137: Italy Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Italy 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Italy 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Italy 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 146: Italy Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Italy 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 149: UK Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: UK 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: UK 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: UK 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 158: UK Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: UK 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 161: Spain Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Spain 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Spain 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 167: Spain Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Spain 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 170: Spain Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Spain Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Spain 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 173: Russia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Russia 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Russia 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 179: Russia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Russia 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 182: Russia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Russia Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Russia 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Rest of Europe 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Europe 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Europe 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Europe 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for High Throughput Screening (HTS) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 212: Australia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Australia 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Australia 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 218: Australia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Australia Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Australia 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 221: Australia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Australia Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Australia 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • INDIA
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 224: India Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: India Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: India 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: India Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: India 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 230: India Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: India Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: India 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 233: India Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: India Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: India 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: South Korea 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: South Korea 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: South Korea Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: South Korea 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: South Korea Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: South Korea 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for High Throughput Screening (HTS) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Latin America 16-Year Perspective for High Throughput Screening (HTS) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Latin America 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Latin America 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Latin America 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Latin America Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Latin America 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Argentina 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Argentina 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Argentina Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Argentina 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Argentina Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: Argentina 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: Brazil 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Brazil 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Brazil Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Brazil 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Brazil Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Brazil 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Mexico 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Mexico 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Mexico Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Mexico 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Mexico Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Mexico 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 313: Rest of Latin America 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 316: Rest of Latin America 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 319: Rest of Latin America 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 322: Rest of Latin America 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for High Throughput Screening (HTS) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 325: Middle East 16-Year Perspective for High Throughput Screening (HTS) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 328: Middle East 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 331: Middle East 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 334: Middle East 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 336: Middle East Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 337: Middle East 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 338: Iran Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 340: Iran 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 341: Iran Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 343: Iran 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 344: Iran Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 345: Iran Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 346: Iran 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 347: Iran Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 348: Iran Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 349: Iran 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 350: Israel Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 352: Israel 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 353: Israel Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 355: Israel 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 356: Israel Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 357: Israel Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 358: Israel 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 359: Israel Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 360: Israel Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 361: Israel 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 364: Saudi Arabia 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 367: Saudi Arabia 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 370: Saudi Arabia 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 372: Saudi Arabia Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 373: Saudi Arabia 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 374: UAE Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 376: UAE 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 377: UAE Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 379: UAE 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 380: UAE Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 381: UAE Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 382: UAE 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 383: UAE Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 384: UAE Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 385: UAE 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 388: Rest of Middle East 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 391: Rest of Middle East 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 394: Rest of Middle East 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 396: Rest of Middle East Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 397: Rest of Middle East 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030
  • AFRICA
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 398: Africa Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 400: Africa 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 401: Africa Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 403: Africa 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 404: Africa Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 405: Africa Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 406: Africa 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 407: Africa Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 408: Africa Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 409: Africa 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제